Umoja Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Umoja Biopharma, Inc.
Former Seagen CEO Siegall Takes Helm At New Biotech Morphimmune
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout
Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.
Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.